NCT ID	NCT02343991
Title	
Phase	Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound
Date Added	Not Applicable 2015-01-22
	Canada
Prior IO Allowed	No
CRC-directed	
Status	Active, not recruiting
Drugs -	Transcranial ExABlate
Tags	MSS/ MMRp
NCT ID	NCT02298959
Title	Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
Phase	Phase 1
Date Added	2014-11-24
Location	Florida, United States Maryland, United States
	Massachusetts, United States
	Canada
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Pembrolizumab, Ziv-Aflibercept, Keytruda, Zaltrap
Tags	MSS/ MMRp
NCT ID	NCT02285816
Title	MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE- A3-Expressing Solid Tumours
Phase	Phase 1, Phase 2
Phase Date Added	
	Phase 1, Phase 2
Date Added	Phase 1, Phase 2 2014-11-07
Date Added Location	Phase 1, Phase 2 2014-11-07 Canada
Date Added Location Prior IO Allowed	Phase 1, Phase 2 2014-11-07 Canada Yes
Date Added Location Prior IO Allowed CRC-directed	Phase 1, Phase 2 2014-11-07 Canada Yes No
Date Added Location Prior IO Allowed CRC-directed Status	Phase 1, Phase 2 2014-11-07 Canada Yes No Active, not recruiting
Date Added Location Prior IO Allowed CRC-directed Status Drugs	Phase 1, Phase 2 2014-11-07 Canada Yes No Active, not recruiting AdMA3, MG1MA3
Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags	Phase 1, Phase 2 2014-11-07 Canada Yes No Active, not recruiting AdMA3, MG1MA3 MSS/ MMRp
Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID	Phase 1, Phase 2 2014-11-07 Canada Yes No Active, not recruiting AdMA3, MG1MA3 MSS/ MMRp NCT02215889
Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title	Phase 1, Phase 2 2014-11-07 Canada Yes No Active, not recruiting AdMA3, MG1MA3 MSS/ MMRp NCT02215889 Partial Liver Segment 2/3 Transplantation Study
Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase	Phase 1, Phase 2 2014-11-07 Canada Yes No Active, not recruiting AdMA3, MG1MA3 MSS/ MMRp NCT02215889 Partial Liver Segment 2/3 Transplantation Study Phase 1
Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added	Phase 1, Phase 2 2014-11-07 Canada Yes No Active, not recruiting AdMA3, MG1MA3 MSS/ MMRp NCT02215889 Partial Liver Segment 2/3 Transplantation Study Phase 1 2014-08-13
Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location	Phase 1, Phase 2 2014-11-07 Canada Yes No Active, not recruiting AdMA3, MG1MA3 MSS/ MMRp NCT02215889 Partial Liver Segment 2/3 Transplantation Study Phase 1 2014-08-13 Norway
Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location Prior IO Allowed	Phase 1, Phase 2 2014-11-07 Canada Yes No Active, not recruiting AdMA3, MG1MA3 MSS/ MMRp NCT02215889 Partial Liver Segment 2/3 Transplantation Study Phase 1 2014-08-13 Norway No
Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed	Phase 1, Phase 2 2014-11-07 Canada Yes No Active, not recruiting AdMA3, MG1MA3 MSS/ MMRp NCT02215889 Partial Liver Segment 2/3 Transplantation Study Phase 1 2014-08-13 Norway No
Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status	Phase 1, Phase 2 2014-11-07 Canada Yes No Active, not recruiting AdMA3, MG1MA3 MSS/ MMRp NCT02215889 Partial Liver Segment 2/3 Transplantation Study Phase 1 2014-08-13 Norway No
Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs	Phase 1, Phase 2 2014-11-07 Canada Yes No Active, not recruiting AdMA3, MG1MA3 MSS/ MMRp NCT02215889 Partial Liver Segment 2/3 Transplantation Study Phase 1 2014-08-13 Norway No Yes Recruiting
Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags	Phase 1, Phase 2   2014-11-07   Canada   Yes   No   Active, not recruiting   AdMA3, MG1MA3   MSS/ MMRp   NCT02215889   Partial Liver Segment 2/3 Transplantation Study   Phase 1   2014-08-13   Norway   No   Yes   Recruiting   MSI-H/ MMRd, MSS/ MMRp   NCT01697371
Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags	Phase 1, Phase 2 2014-11-07 Canada Yes No Active, not recruiting AdMA3, MG1MA3 MSS/ MMRp NCT02215889 Partial Liver Segment 2/3 Transplantation Study Phase 1 2014-08-13 Norway No Yes Recruiting MSI-H/ MMRd, MSS/ MMRp

Date Added	2012-10-02
Location	California, United States
Prior IO Allowed	Yes
CRC-directed	
	No
Status	Recruiting
Drugs –	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT01351103
Title	A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Phase	Phase 1
Date Added	2011-05-10
Location	California, United States Maryland, United States Massachusetts, United States Michigan, United States Texas, United States Canada France Germany Italy Netherlands Spain
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	LGK974, PDR001
Tags	MSS/ MMRp
NCT ID	NCT01174121
Title	Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Phase	Phase 2
Date Added	2010-08-03
Location	Maryland, United States
	Maryland, Onled Otales
Prior IO Allowed	Yes
Prior IO Allowed CRC-directed	
	Yes
CRC-directed	Yes
CRC-directed Status	Yes Yes Recruiting
CRC-directed Status Drugs	Yes Yes Recruiting Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda), Young TIL
CRC-directed Status Drugs Tags	Yes Yes Recruiting Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda), Young TIL MSI-H/ MMRd, MSS/ MMRp
CRC-directed Status Drugs Tags NCT ID	Yes Yes Recruiting Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda), Young TIL MSI-H/ MMRd, MSS/ MMRp NCT01061515 Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal
CRC-directed Status Drugs Tags NCT ID Title	Yes Yes Recruiting Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda), Young TIL MSI-H/ MMRd, MSS/ MMRp NCT01061515 Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
CRC-directed Status Drugs Tags NCT ID Title Phase	Yes Yes Recruiting Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda), Young TIL MSI-H/ MMRd, MSS/ MMRp NCT01061515 Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Phase 1
CRC-directed Status Drugs Tags NCT ID Title Phase Date Added	Yes Yes Recruiting Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda), Young TIL MSI-H/ MMRd, MSS/ MMRp NCT01061515 Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Phase 1 2010-02-03
CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location	Yes Yes Recruiting Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda), Young TIL MSI-H/ MMRd, MSS/ MMRp NCT01061515 Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Phase 1 2010-02-03 Missouri, United States
CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location Prior IO Allowed	Yes Yes Recruiting Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda), Young TIL MSI-H/ MMRd, MSS/ MMRp NCT01061515 Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Phase 1 2010-02-03 Missouri, United States Yes
CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed	Yes Yes Recruiting Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda), Young TIL MSI-H/ MMRd, MSS/ MMRp NCT01061515 Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Phase 1 2010-02-03 Missouri, United States Yes Yes
CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status	Yes Yes Recruiting Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda), Young TIL MSI-H/ MMRd, MSS/ MMRp NCT01061515 Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Phase 1 2010-02-03 Missouri, United States Yes Yes Active, not recruiting

Title	Evaluation for NCI Surgery Branch Immunotherapy Clinical Research Protocols
Phase	
Date Added	1999-11-04
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp